Follow RSS for latest reports on this topicObesity - Market Research and Reports

Obesity: Competitive Landscape to 2026 [Report Updated: 31-10-2018]

Obesity: Competitive Landscape to 2026SummaryObesity is a preventable chronic condition, defined as abnormal or excessive fat accumulation characterized by raised body mass index (BMI ≥30), which is a major risk factor for chronic diseases such as cardiovascular diseases (CVD), diabetes, musculoskeletal disorders, and several major cancers.This report provides an assessment of the pipeline, clin...Read More >>>

Published:
2018-10-31

Published by: Global Data

Prices Starting From:
$3495

Abdominal Obesity Global Clinical Trials Review, H2, 2018 [Report Updated: 25-10-2018]

Abdominal Obesity Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, “Abdominal Obesity Global Clinical Trials Review, H2, 2018 provides an overview of Abdominal Obesity clinical trials scenario. This report provides top line data relating to the clinical trials on Abdominal Obesity. Report includes an overview of trial numbers and their average enrollment in top ...Read More >>>

Published:
2018-10-25

Published by: Global Data

Prices Starting From:
$2500

Obesity - Pipeline Review, H1 2018 [Report Updated: 31-05-2018]

Obesity - Pipeline Review, H1 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2018, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high bloo...Read More >>>

Published:
2018-05-31

Published by: Global Markets Direct

Prices Starting From:
$2500

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease [Report Updated: 01-04-2018]

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular DiseaseSummaryType 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due ...Read More >>>

Published:
2018-04-01

Published by: GBI Research

Prices Starting From:
$6995

Global Obesity Partnering 2012 to 2018 [Report Updated: 01-03-2018]

• Insight into key deal terms included in contracRead More >>>

Published:
2018-03-01

Published by: Current Partnering

Prices Starting From:
$1495

Global and Chinese Obesity Overweight Treatment Industry, 2017 Market Research Report [Report Updated: 17-12-2017]

The 'Global and Chinese Obesity Overweight Treatment Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Obesity Overweight Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Obesity Overweight Treatment manufacturers and is a valuable source of guidance and direction ...Read More >>>

Published:
2017-12-17

Published by: Prof Research

Prices Starting From:
$3000

Global Obesity Partnering 2010 to 2017 [Report Updated: 01-11-2017]

• Insight into key deal terms included in contracRead More >>>

Published:
2017-11-01

Published by: Current Partnering

Prices Starting From:
$1495

Obesity - Pipeline Review, H1 2017 [Report Updated: 23-05-2017]

Obesity - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high bloo...Read More >>>

Published:
2017-05-23

Published by: Global Markets Direct

Prices Starting From:
$2500

Human Microbiome Market by Indication (Obesity, Cancer), Application (Therapeutic, Diagnostic), Product (Prebiotics, Food, Drugs), Product Research (Instruments, Consumables), Technology Research (HTS, Omics Technologies) - Global Forecast to 2025 [Report Updated: 06-03-2017]

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025). Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human m...Read More >>>

Published:
2017-03-06

Published by: MarketsandMarkets

Prices Starting From:
$5650

Abdominal Obesity Global Clinical Trials Review, H1, 2017 [Report Updated: 22-02-2017]

Abdominal Obesity Global Clinical Trials Review, H1, 2017SummaryGlobalData's clinical trial report, “Abdominal Obesity Global Clinical Trials Review, H1, 2017 provides an overview of Abdominal Obesity clinical trials scenario. This report provides top line data relating to the clinical trials on Abdominal Obesity. Report includes an overview of trial numbers and their average enrollment in top ...Read More >>>

Published:
2017-02-22

Published by: Global Data

Prices Starting From:
$2500

Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016SummaryThe diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not curren...Read More >>>

Published:
2016-12-01

Published by: GBI Research

Prices Starting From:
$3995

Global Obesity Partnering 2010 to 2016

Published:
2016-11-01

Published by: Current Partnering

Prices Starting From:
$1495

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss TreatmentSummaryDiabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-...Read More >>>

Published:
2016-08-01

Published by: GBI Research

Prices Starting From:
$4995

Foot Orthotic Insoles Market Analysis: By Type (Custom, Prefabricated); By End User (Sports (Running, Court); Medical (Diabetes, Rheumatoid Arthritis, Plantar Fasciitis, Metatarsalgia, Obesity); Comfort) -With Forecast (2017 - 2022) [Report Updated: 29-02-2016]

Foot orthotic insoles are employed to correct the abnormalities associated with the foot. Foot orthotic insoles work by altering the biomechanics of the foot. The rise in geriatric population over the globe and also lifestyle diseases such obesity, diabetes are the driving factors in this market. The market can be broadly classified into prefabricated and custom foot insoles. Custom Foot Insoles o...Read More >>>

Published:
2016-02-29

Published by: Industry ARC

Prices Starting From:
$5250

Obesity Management Market: By Diet (Meals, Beverages, Weight Loss Supplements and Drugs), By Services (Fitness and Slimming Centre, Diet and Nutrition Consulting Services, others), By Equipment (Fitness, Surgical) & By Geography-Forecast (2016-2021) [Report Updated: 24-02-2016]

Obesity poses an enormous challenge for the developed countries and the lower and middle-income economies. Globally, Technological Advancement, Increasing number of diseases, Personal Disposable income, Increases intake of high calories food and Reduced Physical Activity are the prime growth drivers of global Obesity management market. In addition, emerging economies such as China, India and other...Read More >>>

Published:
2016-02-24

Published by: Industry ARC

Prices Starting From:
$5250

Human Microbiome Market by Indication (Obesity, Cancer), Application (Therapeutic, Diagnostic), Product (Prebiotics, Food, Drugs), Product Research (Instruments, Consumables), Technology Research (High Throughput, Omics Technology) - Global Forecast to 2023

The product segment is expected to account for the largest share of the human microbiome market in the coming years. The high growth in this segment is attributed to the expectations to bring promising microbiome products to the market to help individual for the treatment of chronic diseases and various disorders at early stages and also due to increased curiosity among people to stay fit and have...Read More >>>

Published:
2016-01-12

Published by: MarketsandMarkets

Prices Starting From:
$4650

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class InnovationSummaryObesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the...Read More >>>

Published:
2015-10-01

Published by: GBI Research

Prices Starting From:
$6995

Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020

Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treats a wide range of chronic and refractory disorders but also have fewer side effects. The demand for neuromodulation has increased significantly, because of patients’ preference for minimally invasive surgeries. Moreover, these therapies...Read More >>>

Published:
2015-07-02

Published by: MarketsandMarkets

Prices Starting From:
$5650

Physician Views: A post-AdCom assessment of Novo Nordisk's liraglutide for obesity

Scope Novo Nordisk took an important step in its bid to enter the obesity market last week, when an FDA Advisory Committee voted 14-1 in favour to approve a 3mg version of its diabetes treatment liraglutide for this indication.This outcome reflects validation of the efficacy profile demonstrated by liraglutide in obesity, noted analysts, but importantly also showed that there was minimal concern a...Read More >>>

Published:
2014-09-17

Published by: FirstWord Pharma

Prices Starting From:
$695

Physician Views: What opportunity for Novo Nordisk's Victoza in obesity?

Scope Analysts have notably mixed opinions on the commercial opportunity, but one of the more intriguing near-term catalysts for Novo Nordisk is potential FDA approval of Victoza (its GLP-1 anti-diabetic) for the treatment of obesity. Most recent Phase III data – published in May – supports a consensus view that Victoza will be filed for obesity and stands a strong chance of gaining approval. ...Read More >>>

Published:
2013-11-01

Published by: FirstWord Pharma

Prices Starting From:
$695

Global Obesity Surgery Devices Market Data Survey Report 2025 [Report Updated: 01-01-1970]

SummaryThe global Obesity Surgery Devices market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including:Global market size and forecastRegional market size, production data and export & importKey manufacturers (manufacturing sites, capacity and production, product specifications etc.)Major ApplicationMajor TypeKey manufacturers are included based o...Read More >>>

Published:

Published by: HeyReport

Prices Starting From:
$1500